2013
Updates in therapy for uterine serous carcinoma
Roque DM, Santin AD. Updates in therapy for uterine serous carcinoma. Current Opinion In Obstetrics & Gynecology 2013, 25: 29-37. PMID: 23138439, DOI: 10.1097/gco.0b013e32835af98d.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaSerous carcinomaTreatment of USCPaclitaxel-resistant diseasePI3/Akt/mTOR pathwayClass III β-tubulinEarly-stage diseaseNew target antigensAKT/mTOR pathwayVascular endothelial growth factorDistinct molecular pathogenesisHER2/neuIII β-tubulinCurrent clinical approachesEndothelial growth factorNovel microtubule-stabilizing agentEndometrial cancerAggressive variantOptimal therapyProspective studyPathway aberrationsClinical investigationSmall molecule inhibitorsTarget antigenClinical approach
2012
Targeted therapy for high-risk endometrial carcinoma
Roque D, Schwartz P, Santin A. Targeted therapy for high-risk endometrial carcinoma. Journal Of Clinical Practice 2012, 9: 539-554. DOI: 10.2217/cpr.12.44.Peer-Reviewed Original ResearchType II endometrial cancerEndometrial cancerHigh-risk endometrial carcinomaHigh-risk cancerAggressive clinical courseRational therapeutic strategiesMolecular pathway alterationsClinical courseEndometrial carcinomaPoor prognosisClinical behaviorDisease burdenTargeted therapyTherapeutic strategiesSmall molecule inhibitorsClinical advancesPathway alterationsDistinct histopathologyCytotoxic agentsCancerCurrent standardImmunotherapyMolecular characterizationCarcinomaPrognosis